Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648377 | 0.93 | GCGR (0.73) | GCGR | |
| SCHEMBL2653781 | 0.92 | GCGR (0.61) | GCGR | |
| SCHEMBL2649026 | 0.84 | GCGR (0.68) | GCGR | |
| SCHEMBL30661851 | 0.83 | GCGR (1.00) | GCGR | |
| SCHEMBL2648640 | 0.83 | GCGR (0.69) | GCGR | |
| SCHEMBL105891 | 0.83 | GCGR (1.00) | GCGR | |
| SCHEMBL2647444 | 0.83 | GCGR (0.51) | GCGR | |
| SCHEMBL2648372 | 0.82 | GCGR (0.70) | GCGR | |
| SCHEMBL2647208 | 0.82 | GCGR (0.85) | GCGR | |
| SCHEMBL2662506 | 0.81 | GCGR (0.51) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2213289-A1 | Combination treatment for diabetes mellitus | Nycomed GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | GCGR 154/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | GCGR 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.